Switching from Epogen to oral vadadustat for dialysis anemia
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests whether taking an oral pill three times a week (vadadustat) works as well as injections (Epogen) to treat anemia—low red blood cells—in people on dialysis. If it works, a pill might be easier and more convenient than injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You receive in-center hemodialysis at least three times per week for kidney failure
- You are currently receiving Epogen (erythropoietin) injections, not on a break from them
- Your recent blood hemoglobin levels are stable (between 9–11.4 g/dL) and iron stores are adequate
- You have not missed more than two dialysis sessions in the past month
- Your liver function is normal or only mildly elevated, with no active liver disease or cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests whether a new medication called vadadustat can help dialysis patients manage anemia (low red blood cells), improve their quality of life, and reduce inflammation. You would take this medication alongside your current dialysis treatment.
This trial tests a new oral medication (QLG1218, also called daprodustat) to treat anemia in people with chronic kidney disease who are on hemodialysis. It is comparing the new drug to the usual injected ESA medicines to see if it works as well or better.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
Hear when a new Anemia Associated With Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.